dihexa approval status fda 10MG : COA Tested Research peptide Dihexa Peptide in Austin, TX

Pharmacokinetic studies demonstrated approximately 38% oral bioavailability and blood-brain barrier penetration, unusual for a peptide-based compound and attributable to Dihexa's small size (504.66 Da) and hydrophobic modifications

Answer: Cagrilintide engages the amylin pathway on several fronts: it activates satiety centers in the brainstem, slows gastric emptying so meals satisfy longer, helps stabilize post-meal blood sugar, and appears to reduce reward-driven cravings for highly palatable foods

10.1016/j.thromres.2011.07.035 135 StupnisekM.KokotA.DrmicD.Hrelec PatrljM.Zenko SeverA.KolencD.et al (2015)

Peer-reviewed research supports its application in cognitive enhancement and neurodegenerative disease contexts